“Voriconazole Pharmacokinetics Following Hsct: Results From The Bmt Ctn 0101 Trial.”. J Antimicrob Chemother 71 (8). J Antimicrob Chemother: 2234-40. doi:10.1093/jac/dkw127.
. 2016. “Induction Of Hiv-1-Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 Hiv-1 Vaccination Of Humans.”. J Infect Dis 211 (4). J Infect Dis: 518-28. doi:10.1093/infdis/jiu485.
. 2015. “First-In-Human Evaluation Of A Hexon Chimeric Adenovirus Vector Expressing Hiv-1 Env (Ipcavd 002).”. J Infect Dis 210 (7). J Infect Dis: 1052-61. doi:10.1093/infdis/jiu217.
. 2014. “First-In-Human Evaluation Of The Safety And Immunogenicity Of A Recombinant Adenovirus Serotype 26 Hiv-1 Env Vaccine (Ipcavd 001).”. J Infect Dis 207 (2). J Infect Dis: 240-7. doi:10.1093/infdis/jis670.
. 2013. “Safety And Immunogenicity Of Modified Vaccinia Ankara In Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial.”. J Infect Dis 207 (12). J Infect Dis: 1888-97. doi:10.1093/infdis/jit105.
. 2013. “Comparative Outcomes Of Donor Graft Cd34+ Selection And Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis For Patients With Acute Myeloid Leukemia In Complete Remission Undergoing Hla-Matched Sibling Allogeneic Hematopoietic Cell Transpl”. J Clin Oncol 30 (26). J Clin Oncol: 3194-201. doi:10.1200/JCO.2012.41.7071.
. 2012. “Randomized, Double-Blind Trial Of Fluconazole Versus Voriconazole For Prevention Of Invasive Fungal Infection After Allogeneic Hematopoietic Cell Transplantation.”. Blood 116 (24). Blood: 5111-8. doi:10.1182/blood-2010-02-268151.
. 2010.